- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05131113
Stratification of Patients in Oncogeriatrics and Personalization of Interventions (ONKO-FRAIL)
Multicenter randomized controlled trial. Patients will be randomly assigned to the control group or the intervention group in each of the health centers.
The control group will receive the usual care, while the intervention group will add an individualized physical exercise program to the usual care.
Cancer is a disease of the elderly. More than 65% of all malignancies affect this population. At the same time, the incidence of cancer cases increases and the need to better understand the biological characteristics of the disease, as well as those of the elderly who suffer from it, is highlighted.
Oncogeriatrics is the area that addresses the care of the elderly patient with cancer, taking into account that physiological aging causes older people to have their own characteristics that require a differential approach in care. The low inclusion in clinical trials of elderly patients and the few specific trials carried out in this subpopulation together with the progressive aging of the population mean that the development of this area has become a priority in health policies.
Therefore, there is a need to focus the research area on supervised physical exercise in older people with cancer in an innovative way, with the aim of generating new hypotheses that overcome existing limitations and facilitate the introduction into the health system of this type of interventions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It seems useful to have instruments that help to objectively evaluate the fragilty and comorbidity of patients with the intention of adequately indicating the administration of antineoplastic treatment. In addition, nowadays, with the arrival of new less toxic treatments, it is essential to make a good selection of the patients to be treated, since there is a risk of treating patients who are not going to benefit from an active treatment just for having more comfortable medications and with less toxicity.
There are several instruments that can help to better select the patients that the investigators are going to treat and to select the supportive care that can help to better tolerate the proposed treatments while maintaining the best possible quality of life. Some of those instruments are aimed at detecting fragility such as comprehensive geriatric assessment. They identify in more detail the different vulnerabilities that can affect the patient in the benefit vs. toxicity balance of the treatment and in the long-term quality of life
Many authors emphasize the importance of including a physical exercise program during and after cancer treatment. Despite this, older people with cancer usually have low levels of physical activity, and few adhere to the recommendations they receive from health centers. For this reason, involving older people with cancer in a regular physical activity program becomes a challenge for those in charge of health centers.
Some studies have shown that physical exercise can reduce the usual loss of functional capacity and reduce frailty during cancer treatment. On the other hand, physical exercise can help reduce pain, toxicity and improve the completion rate of systemic treatment. Recent studies have found that physical exercise on the days of chemotherapy cycles is safe and may be beneficial in reducing neuropathy and maintaining physical well-being. Additionally, physical exercise can impact one of the most common and strenuous adverse effects of cancer treatment, fatigue.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Clinical Research Platform Biogipuzkoa Health Research Institute
- Phone Number: + 34 943 006140
- Email: OSID.INVESTCLINICA@osakidetza.eus
Study Locations
-
-
-
Bilbao, Spain, 48013
- Recruiting
- Hospital Universitario Basurto
-
-
Guipuzcoa
-
San Sebastián, Guipuzcoa, Spain, 20014
- Recruiting
- Hospital Universitario Donostia
-
Contact:
-
-
Álava
-
Vitoria, Álava, Spain, 01009
- Recruiting
- Hospital Universitario de Araba
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 70 or over.
- Solid cancer.
- Candidates for systemic treatment (chemotherapy, hormone therapy, biological therapies or immunotherapy) if the time that has elapsed since the last dose of treatment has been at least 1 month (washout period).
- Patients with breast, gynecological, lung, pleural, digestive, urological, ENT area, sarcomas, brain tumors, melanomas and patients with tumors of unknown origin will be included.Regarding tumor type and stage for patients with lymphoma: 1) Diffuse large B-cell NHL: include stages I-II if Bulky (>7.5 cm) or R-IPI>1. 2) Hodgkin lymphoma: stages I-II if Bulky (>10 cm). 3) Follicular NHL and marginal NHL without GELF treatment criteria. 4) 80 years old receiving 6 R-mini CHOP cycles.
Exclusion Criteria:
- ECOG ≥3
- cases of advanced dementia
- serious psychiatric illnesses
- Lack of basic fluency in the Basque or Spanish language
- those patients unable to get up from the chair and walk independently with or without auxiliary device.
- Neither will those patients who participate in other studies in which they are undertaking a physical exercise program be included.
- Absolute or relative contraindications in which the risk of adverse effects outweighs the possible benefits such as unstable angina, acute symptomatic heart failure ...
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventionist group
The interventional group will add an individualized physical exercise program to the usual care.
|
Physical exercise
|
No Intervention: Control group
The control group will receive the usual care and hygiene recommendations of the movement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short Physical Performance Battery
Time Frame: 12 weeks
|
Short Physical Performance Battery (SPPB) evaluates balance, gait ability, and leg strength using a single tool.
The score for each part is given in categorical modality (0-4).
The best score will be 12 points.
1 point of change in the total score has demostrated to be of clinical relevance.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Integral Geriatric Assessment -Socio-familial situation:
Time Frame: 12 weeks
|
Abbreviated Gijón Scale (3-15 pts)
|
12 weeks
|
Integral Geriatric Assessment - Basic Activities of Daily Living ( BADL):
Time Frame: 12 weeks
|
Barthel Index (0-100 pts)
|
12 weeks
|
Integral Geriatric Assessment -Instrumental Activities of Daily Living (IADL):
Time Frame: 12 weeks
|
Lawton´s test (0-8 pts)
|
12 weeks
|
Integral Geriatric Assessment -Cognitive function:
Time Frame: 12 weeks
|
Pfeiffer test (0-10 pts)
|
12 weeks
|
Integral Geriatric Assessment - Depression:
Time Frame: 12 weeks
|
Yesavage test-short form (0-15 pts) (Yes/No)
|
12 weeks
|
Integral Geriatric Assessment -Nutritional status:
Time Frame: 12 weeks
|
MNA-SF test (0-14)
|
12 weeks
|
Integral Geriatric Assessment -Polypharmacy:
Time Frame: 12 weeks
|
Number of chronic drugs consumed by the patient
|
12 weeks
|
Integral Geriatric Assessment - Geriatric syndromes:
Time Frame: 12 weeks
|
Immobility and pressure ulcers (Yes/No); instability and falls (Yes/No); urinary and faecal incontinence (Yes/No); dementia and acute confusional syndrome ( Yes//No); malnutrition (Yes/No); alterations in sight and hearing (Yes/No);constipation, faecal impaction (Yes/No);depression/insomnia (Yes/No)
|
12 weeks
|
Integral Geriatric Assessment -Pain:
Time Frame: 12 weeks
|
VAS (0-10 pts)
|
12 weeks
|
Integral Geriatric Assessment - Emotional distress:
Time Frame: 12 weeks
|
Stress thermometer (0-10 pts)
|
12 weeks
|
Cognitive function
Time Frame: 12 weeks
|
- Montreal Cognitive Assessment (MOCA) test (0-30 pts)
|
12 weeks
|
Anthropometry - Weight:
Time Frame: 12 weeks
|
Unit of measure: kg
|
12 weeks
|
Anthropometry - Height:
Time Frame: 12 weeks
|
Unit of measure: cm
|
12 weeks
|
Anthropometry -Waist, hip and calf circumference:
Time Frame: 12 weeks
|
Unit of measure: cm
|
12 weeks
|
Anthropometry -Blood pressure:
Time Frame: 12 weeks
|
- Unit of measure: mmHg
|
12 weeks
|
Anthropometry 1: - Bioimpedance (in some centers) 1
Time Frame: 12 weeks
|
· Resistance (Ω)
|
12 weeks
|
Anthropometry 2: - Bioimpedance (in some centers) 1
Time Frame: 12 weeks
|
· Phase angle (º)
|
12 weeks
|
Biomarkers>> a.1 Inflammation markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- Interleukins 1beta, 2, 4, 6, and 8 (IL-1 b, IL-2, IL-4, IL-6, and IL-8/CXCL8).
|
12 weeks
|
Biomarkers>> a.2 Inflammation markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- Tumor necrosis factor alpha (TNFa)
|
12 weeks
|
Biomarkers>> a.3 Inflammation markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- Interferon gamma (IFN)
|
12 weeks
|
Biomarkers>> a.4 Inflammation markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- C-reactive protein (CRP)
|
12 weeks
|
Biomarkers>> a.5 Inflammation markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- Brain-derived neurotrophic factor (BDNF)
|
12 weeks
|
Biomarkers>> a.6 Inflammation markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- CMV serology
|
12 weeks
|
Biomarkers>> b.1 Endocrine-nutritional and muscle wasting markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- Insulin-derived growth factor (IGF-1).
|
12 weeks
|
Biomarkers>> b.2 Endocrine-nutritional and muscle wasting markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- Dehydroepiandrosterone sulfate (DHEA sulfate)
|
12 weeks
|
Biomarkers>> b.3 Endocrine-nutritional and muscle wasting markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- Vitamin D
|
12 weeks
|
Biomarkers>> b.4 Endocrine-nutritional and muscle wasting markers (pg/ml or ng/ml):
Time Frame: 12 weeks
|
- Albumin
|
12 weeks
|
Biomarkers>> c. Hematological (AU):
Time Frame: 12 weeks
|
Biomarkers in the cell fraction of blood samples.
Panel of 7 genes related to aging and frailty in RNA extracted from blood leukocytes, by quantitative PCR (qPCR): EGR1, Hsa-miR454, DDX11L1, G0S2, GJB6, CXCL8 and NSF.
This panel has been developed at Biodonostia as a diagnostic and frailty stratification tool (European Patent Application EP3599286).
|
12 weeks
|
Functional assessment and frailty: - Steep Ramp test (A)
Time Frame: 12 weeks
|
>Heart rate (bpm)
|
12 weeks
|
Functional assessment and frailty: - Steep Ramp test (B)
Time Frame: 12 weeks
|
>Time spent cycling (min/sec)
|
12 weeks
|
Functional assessment and frailty: - Steep Ramp test (C)
Time Frame: 12 weeks
|
> Maximum W
|
12 weeks
|
Functional assessment and frailty: - Frailty
Time Frame: 12 weeks
|
G8 scale ( 0-17); Fried Frailty Phenotype (0-5 pts)
|
12 weeks
|
Functional assessment and frailty: - Dynamic balance:
Time Frame: 12 weeks
|
8 Foot Up and Go Test (8FUGT) (sec)
|
12 weeks
|
Functional assessment and frailty: - Physical activity: 1.Accelerometry
Time Frame: 12 weeks
|
Sleep efficiency (%)
|
12 weeks
|
Functional assessment and frailty: - Physical activity: 2. Accelerometry
Time Frame: 12 weeks
|
Moderate too vigorous physical activity (min/d)
|
12 weeks
|
Functional assessment and frailty: - Physical activity: 3. Accelerometry
Time Frame: 12 weeks
|
Sedentary time (h/d)
|
12 weeks
|
Functional assessment and frailty: - Physical activity: 4. Accelerometry
Time Frame: 12 weeks
|
Light physical activity (min/d)
|
12 weeks
|
Patient-reported outcomes (PRO): -Fatigue:
Time Frame: 12 weeks
|
EORTC QLQ-FA12
|
12 weeks
|
Patient-reported outcomes (PRO): - Quality of life:
Time Frame: 12 weeks
|
EORTC QLQ-C30
|
12 weeks
|
Patient-reported outcomes (PRO): - Nutrition:
Time Frame: 12 weeks
|
Simplified Nutritional Appetite Questionnire
|
12 weeks
|
Patient-reported outcomes (PRO): - Cognition:
Time Frame: 12 weeks
|
Cognitive Failures Questionnaire
|
12 weeks
|
Patient-reported outcomes (PRO): - Physical activity:
Time Frame: 12 weeks
|
Godin Physical Activity Questionnaire
|
12 weeks
|
Adverse events (CTCAE)
Time Frame: 12 weeks
|
|
12 weeks
|
Factors related to physical exercise adherence
Time Frame: 12 weeks
|
Beliefs, barriers, facilitators and self-efficacy in relation to physical exercise ( self-developed questionnaire)
|
12 weeks
|
Intervention assessment - Follow-up of the intervention
Time Frame: 12 weeks
|
Self- developed questionnaire
|
12 weeks
|
Intervention assessment - Adverse events associated with the intervention
Time Frame: 12 weeks
|
Self- developed questionnaire
|
12 weeks
|
Intervention assessment - Satisfaction with the intervention
Time Frame: 12 weeks
|
Self- developed questionnaire
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONKO-FRAIL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oncology
-
State University of New York at BuffaloRecruitingMedical Oncology | Integrative Oncology | Medical Nutrition TherapyUnited States
-
State University of New York at BuffaloRecruitingMedical Oncology | Integrative Oncology | Medical Nutrition TherapyUnited States
-
AmMax Bio, Inc.CompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
MaineHealthTufts Medical CenterRecruitingOncology | Prehabilitation | Surgical OncologyUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
Royal Marsden NHS Foundation TrustRecruiting
-
GuerbetRecruitingOncologyAustria, France, Switzerland
-
Centre Hospitalier Regional de HuyCompleted
Clinical Trials on Physical exercise
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Universidade Estadual da ParaibaUniversity of Campinas, BrazilUnknown
-
Instituto de Cardiologia do Rio Grande do SulFundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, BrazilTerminatedObesity | Sedentary Lifestyle | Hypercholesterolemia | High Blood PressureBrazil
-
Clarice Maria de Lucena MartinsCompletedMetabolic Diseases | Physical Activity
-
McGill UniversityUniversité du Québec à Trois-Rivières; Université de Montréal; Concordia University... and other collaboratorsRecruiting
-
National Research Centre for the Working Environment...CompletedMusculoskeletal DisordersDenmark
-
Cardiff UniversityCompletedParkinson's DiseaseUnited Kingdom
-
Instituto Materno Infantil Prof. Fernando FigueiraCompleted
-
Universidad Católica San Antonio de MurciaCompleted
-
Göteborg UniversityVastra Gotaland Region; Sahlgrenska University Hospital, SwedenCompletedChronic Widespread PainSweden